The Effects of Iproniazid Phosphate (Marsilid) on Hypertension

Nussbaum, Harvey E.; Leff, William A.; Mattia, Virginius D.; Hillman, Ernest

doi:10.1177/000331975700800210

Cited by 17 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 1957 extensive clinical trials confirmed the positive results of Kline, Crane, and Scherbel, and iproniazid became the first of the monoamine oxidase inhibitors to be used in antidepressant therapy. In fact, the drug has found additional use, e.g., in relieving hypertension (17) and angina pectoris (78). On November 29-30,1957, Hoffmann-La Roche, Inc. sponsored a 26-paper "Symposium on the Biochemical and Clinical Aspects of Marsalid and Other Monoamine Oxidase Inhibitors" (79).…”

mentioning

confidence: 99%

The discovery of iproniazid and its role in antidepressant therapy

Kauffman¹

1979

J. Chem. Educ.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

The discovery of iproniazid and its role in antidepressant therapy

Kauffman¹

1979

J. Chem. Educ.

View full text Add to dashboard Cite

show abstract

“…Another action of iproniazid is reduction in blood pressure; this effect is more marked at high dosage levels and occurs even in normotensive patients (9). Nussbaum et al (10) reported that in 16 severely hypertensive patients treated with iproniazid for a two‐month period, the blood pressure was lowered and there was marked subjective improvement. In a similar study Harnes (11) found that the hypotensive effect of iproniazid occurred mainly when the patient was in the standing position, although in one‐third of his cases the decrease in blood pressure occurred with the subject in the supine position.…”

mentioning

confidence: 99%

Iproniazid in the Treatment of Resistant Hypertension

Dyne¹

1960

J American Geriatrics Society

View full text Add to dashboard Cite

Iproniazid Hepatitis

Felix¹,

Schwartz²,

Rifkin³

1959

AMA Arch Intern Med

View full text Add to dashboard Cite

Iproniazid * (1-isonicotinyl-2-isopropyl\x=req-\ hydrazine) was initially introduced to clinical medicine as an antituberculous agent in 1952.1 Although potent in its therapeutic effect, the drug was eventually abandoned in favor of its chemical relative, isoniazid, largely because of its distressing si de\ x=req-\ effects. In addition to its antituberculous activity, early studies with iproniazid clearly indicated a striking nonspecific action in promoting elevation of mood, stimulating appetite, and increasing sense of well-being.In view of these nonspecific effects, the drug has been recently reintroduced as a "psychic energizer" in the management of psychiatric depression, with favorable results.2,3 Furthermore, there are indications that this agent is now being used in a large variety of medical disorders. Reports concerning the use of iproniazid in hypertension,4 rheumatoid arthritis,5 and angina pectoris6 have already appeared in the literature.Of the early-recognized side-effects of iproniazid, those resulting from undesirable actions on the autonomic and central nervous systems are most frequent. These include vertigo, insomnia, hyper-reflexia. muscular twitching, convulsions, paresthe-sias, postural hypotension, dry mouth, de¬ layed micturition, and constipation. Perhaps the most serious, and certainly the least-< documented toxic effect, is jaundice. In an effort to clarify further the status of jaun¬ dice as a significant toxic effect of iproniazid therapy, the following five case reports and review of pertinent literature are pre¬ sented.Case 1.-A 49-year-old white woman was ad¬ mitted to Montefiore Hospital on Jan. 25, 1958, because of jaundice of two weeks' duration. Iproniazid therapy had been instituted two months prior to admission because of depression. After a fourweek period of treatment, during which time she took 150 mg. of iproniazid daily for a total of 4.2 mg., the drug was discontinued. Two weeks after cessation of therapy, the patient first noticed jaundice, dark urine, and light-colored stools. Liverfunction tests three days prior to admission revealed a total serum bilirubin of 8.2 mg. '%, cephalin flocculation of 3+, thymol turbidity of 10.0 units, and alkaline phosphatase of 5.5 Bessy-Lowry units. The patient denied all gastrointestinal symptomatol¬ ogy. Although an oral cholecystogram performed three years previously revealed a single gallbladder calculus, she specifically denied previous jaundice as well as recent fever, abdominal pain, dyspepsia, or vomiting. She did not drink alcoholic beverages and was not exposed to jaundiced persons, injec--< tions, or hepatotoxic agents, excluding iproniazid, for at least six months. Her only other medication during this period was an occasional capsule of secobarbital at bedtime. Physical examination revealed a well-nourished, grossly icteric but alert, middle-aged woman in no acute distress. The temperature was 99 F; thep ulse rate, 72, and the blood pressure, 160/90. There were no significant physical findings except jaundice and a soft,...

show abstract

The Effects of Iproniazid Phosphate (Marsilid) on Hypertension

Cited by 17 publications

References 3 publications

The discovery of iproniazid and its role in antidepressant therapy

The discovery of iproniazid and its role in antidepressant therapy

Iproniazid in the Treatment of Resistant Hypertension

Iproniazid Hepatitis

Contact Info

Product

Resources

About